Who
Mark Elliott Boulding
Exec. VP and CLO
Company insider
Files Form 4 as: Exec. VP and CLO, PTC Therapeutics.
In numbers
- Trades disclosed
- 441
- Buys
- 0
- Sells
- 63
- Bought
- $0
- Sold
- $44.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Jan 2014
- Last trade
- 9 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Oct 2026filed 13 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $7,569192 at $39.42 | filing |
| 9 Oct 2026filed 13 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K192 at $64.26 | filing |
| 9 Oct 2026filed 13 Oct 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —192 at $0.00 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $17K435 at $39.42 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K435 at $64.16 | filing |
| 6 Oct 2026filed 7 Oct 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —435 at $0.00 | filing |
| 5 Oct 2026filed 7 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $65K1,638 at $39.42 | filing |
| 5 Oct 2026filed 7 Oct 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $105K1,638 at $64.03 | filing |
| 5 Oct 2026filed 7 Oct 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,638 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $72K2,813 at $25.69 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $133K1,844 at $72.39 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $71K969 at $72.90 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,813 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,813 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $72K2,813 at $25.69 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $133K1,844 at $72.39 | filing |
| 17 Aug 2026filed 19 Aug 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $71K969 at $72.90 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Code M | $89K2,266 at $39.42 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PTCT PTC TherapeuticsBiotechnology | SEC FORM 4 Sold | $64K745 at $86.38 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PTCT PTC Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,226 at $0.00 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Sharesthemarketsdaily.com · 9 Oct 2026PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026PTCT · prnewswire.com · 15 Oct 2026
1 headline in the last 90 days name Mark Elliott Boulding; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.